1. Academic Validation
  2. Rational Chemical Design of Molecular Glue Degraders

Rational Chemical Design of Molecular Glue Degraders

  • ACS Cent Sci. 2023 Apr 11;9(5):915-926. doi: 10.1021/acscentsci.2c01317.
Ethan S Toriki 1 2 3 James W Papatzimas 1 2 3 Kaila Nishikawa 1 2 3 Dustin Dovala 2 4 Andreas O Frank 2 4 Matthew J Hesse 2 4 Daniela Dankova 1 2 3 Jae-Geun Song 2 4 Megan Bruce-Smythe 2 4 Heidi Struble 2 4 Francisco J Garcia 2 5 Scott M Brittain 2 5 Andrew C Kile 2 4 Lynn M McGregor 2 5 Jeffrey M McKenna 2 5 John A Tallarico 2 5 Markus Schirle 2 5 Daniel K Nomura 1 2 3 6
Affiliations

Affiliations

  • 1 Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, United States.
  • 2 Novartis-Berkeley Translational Chemical Biology Institute, Berkeley, California 94720, United States.
  • 3 Innovative Genomics Institute, Berkeley, California 94704, United States.
  • 4 Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.
  • 5 Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.
  • 6 Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California 94720, United States.
Abstract

Targeted protein degradation with molecular glue degraders has arisen as a powerful therapeutic modality for eliminating classically undruggable disease-causing proteins through proteasome-mediated degradation. However, we currently lack rational chemical design principles for converting protein-targeting ligands into molecular glue degraders. To overcome this challenge, we sought to identify a transposable chemical handle that would convert protein-targeting ligands into molecular degraders of their corresponding targets. Using the CDK4/6 inhibitor ribociclib as a prototype, we identified a covalent handle that, when appended to the exit vector of ribociclib, induced the proteasome-mediated degradation of CDK4 in Cancer cells. Further modification of our initial covalent scaffold led to an improved CDK4 Degrader with the development of a but-2-ene-1,4-dione ("fumarate") handle that showed improved interactions with RNF126. Subsequent chemoproteomic profiling revealed interactions of the CDK4 Degrader and the optimized fumarate handle with RNF126 as well as additional RING-family E3 Ligases. We then transplanted this covalent handle onto a diverse set of protein-targeting ligands to induce the degradation of BRD4, Bcr-Abl and c-ABL, PDE5, AR and AR-V7, Btk, LRRK2, HDAC1/3, and SMARCA2/4. Our study undercovers a design strategy for converting protein-targeting ligands into covalent molecular glue degraders.

Figures
Products